In-Depth Analysis of Selinexor (Xpovio): A Novel Nuclear Export Blockade Option for Relapsed/Refractory Multiple Myeloma and Latest Clinical Advances

　　1.Mechanism:First-in-Class XPO1 Inhibitor

　　Selinexor(brand name Xpovio)is an oral selective inhibitor of nuclear export protein XPO1(CRM1).By blocking XPO1,it causes accumulation of tumor suppressor proteins in the nucleus,reactivating cell cycle control and inducing apoptosis.This provides a novel"nuclear export blockade"approach for relapsed/refractory multiple myeloma(RRMM).

　　2.Approved Indications

　　In combination with bortezomib and dexamethasone for adult patients with at least 1 prior therapy.

　　In combination with dexamethasone for adult patients with RRMM who have received≥4 prior therapies and are refractory to≥2 proteasome inhibitors,≥2 immunomodulatory agents,and 1 anti-CD38 monoclonal antibody.

　　3.Dosing Regimens

　　With bortezomib&dexamethasone:100 mg orally once weekly on Day 1.

　　With dexamethasone alone:80 mg orally on Day 1 and Day 3 of each week(total 160 mg/week).Tablets must be swallowed whole;dose adjustments should be guided by a physician.

　　4.Toxicity Management

　　Common adverse events include hematologic toxicities(thrombocytopenia,neutropenia,anemia)and non-hematologic issues(fatigue,nausea,decreased appetite,diarrhea,weight loss,hyponatremia).Most are dose-dependent and manageable via dose modification and supportive care.Regular monitoring of blood counts,sodium,and liver/kidney function is required.

　　5.Key Clinical Trials

　　STORM:In heavily pretreated patients,selinexor+dexamethasone achieved an ORR of~25%and median OS of~8.4 months.

　　BOSTON:XVd regimen showed median PFS of 13.9 months vs 9.5 months for Vd alone,with ORR of 76%-78%.

　　STOMP:Exploratory study combining selinexor with carfilzomib,showing promising response rates.

　　6.Pricing and Availability

　　The originator drug is priced at a relatively high level,while generic versions in some overseas markets are available at comparatively lower costs.Patients should verify manufacturing qualifications,storage conditions,and legal import requirements before purchasing,and always consult their oncologist.

　　7.2025–2026 Global Clinical Updates

　　A 2025 ASH study showed no PFS benefit when adding selinexor to lenalidomide maintenance after transplant,with higher adverse events.The SENTRY Phase III trial(selinexor+ruxolitinib for myelofibrosis)is ongoing,with data expected in 2026.Real-world studies on low-dose intermittent dosing aim to reduce toxicity while preserving efficacy.

　　8.FAQ

　　Can it be used alone?​Combination is standard;monotherapy is limited to specific refractory cases.

　　Most concerning side effects?​Thrombocytopenia and fatigue,mostly manageable with monitoring.

　　Missed dose?​Do not double the dose;follow physician instructions.

　　Herbal supplements?​Some may affect metabolism;inform your doctor.

　　Who should avoid it?​Patients with severe organ dysfunction or poor performance status require careful evaluation.